Article
Author(s):
Treatment shows promise in fighting lymphoma in early studies.
A new approach has been created with the potential to simultaneously speed up and improve the process of T-cell therapy, according to a recent study.
The study was conducted by researchers at the Fred Hutchinson Cancer Research Center and published in Nature Biotechnology.
T-cell therapy is a form of immunotherapy that uses a patient’s own T-cells that are engineered to carry new proteins that can attack cancer.
In the study, researchers used a special, small protein tag that could purify and track T-cells after they were engineered. This new approach was performed to examine its effects on a mouse model of lymphoma and on human cancerous cells in the laboratory.
Researchers believe that this new approach could improve current T-cell therapy methods by boosting the potency of cells; growing larger numbers of cancer fighting T-cells; adding a potential “kill switch” that can deactivate cells quickly in the event of toxic side effects; and cutting down the amount of time for immune cell processing from 14 to 20 days to 9 days or less.